Abstract: Novel serine/threonine receptor proteins and BMP receptor proteins are disclosed, as well as DNA molecules encoding said proteins and methods of using the receptor proteins. Further disclosed are truncated BMP receptor proteins and molecules which act as ligands to said BMP receptor proteins.
Type:
Grant
Filed:
September 17, 1993
Date of Patent:
September 18, 2001
Assignee:
Genetics Institute, Inc.
Inventors:
John M. Wozney, Anthony J. Celeste, R. Scott Thies, Noboru Yamaji
Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Beta enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
Abstract: Purified bone morphogenetic protein-9 (BMP-9) proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
June 6, 1994
Date of Patent:
September 11, 2001
Assignee:
Genetics Institute, Inc.
Inventors:
Vicki A. Rosen, John M. Wozney, Anthony J. Celeste, R. Scott Thies, Jeffrey R. Song
Abstract: Compositions of proteins with tendon/ligament-like tissue inducing activity are disclosed. The compositions are useful in the treatment of tendinitis and tendon or ligament defects and in related tissue repair.
Type:
Grant
Filed:
February 28, 1997
Date of Patent:
September 4, 2001
Assignees:
Genetics Institute, Inc., President and Fellows of Harvard College
Inventors:
Anthony J. Celeste, John M. Wozney, Vicki A. Rosen, Neil M. Wolfman, Gerald H. Thomsen, Douglas A. Melton
Abstract: Fusions proteins comprising P-selectin ligand proteins are disclosed, including fusions with immunoglobulins, BMPs, AGP and IL-11. Polynucleotides encoding such fusions are also disclosed.
Type:
Grant
Filed:
August 30, 1996
Date of Patent:
August 21, 2001
Assignee:
Genetics Institute, Inc.
Inventors:
Glenn R. Larsen, Dianne S. Sako, Xiao-Jia Chang, Geertruida M. Veldman, Dale Cumming, Ravindra Kumar, Gray Shaw
Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding the enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
Abstract: Polynucleotides encoding the human IL-11 receptor and fragments thereof are disclosed. IL-11 receptor proteins, methods for their production, inhibitors of binding of human IL-11 and its receptor and methods for their identification are also disclosed.
Abstract: The present invention provides novel formulations comprising IL-11 and glycine. Also provided are compositions, both liquid and lyophilized, comprising IL-11 and glycine and optionally, a buffering agent such as histidine and phosphate.
Abstract: Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced diarrheal diseases (Clostridium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial infarction (MI) or cerebral vascular accident (CVA), aphthous ulcers (oral), atherosclerosis (plaque rupture), prevention of tumor metastases, asthma, preeclampsia, and allergic disorders such as rhinitis, conjunctivitis, and urticaria.
Abstract: IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
Type:
Grant
Filed:
April 30, 1997
Date of Patent:
July 31, 2001
Assignee:
Genetics Institute, Inc.
Inventors:
Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
Abstract: IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor methods of mediating-Ig-responses and methods for their identification are also disclosed.
Type:
Grant
Filed:
April 30, 1997
Date of Patent:
June 19, 2001
Assignee:
Genetics Institute, Inc.
Inventors:
Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
Abstract: Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
September 9, 1997
Date of Patent:
June 12, 2001
Assignee:
Genetics Institute, Inc.
Inventors:
Elizabeth A. Wang, John M. Wozney, Vicki A. Rosen
Abstract: Disclosed herein is a method of determining whether a first protein is capable of physically interacting with a second protein, involving: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein including the first protein covalently bonded to a binding moiety which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the second protein covalently bonded to a gene activating moiety and being conformationally-constrained; and (b) measuring expression of the reporter gene as a measure of an interaction between the first and the second proteins. Also disclosed are methods for assaying protein interactions, and identifying antagonists and agonists of protein interactions.
Type:
Grant
Filed:
February 12, 1999
Date of Patent:
June 5, 2001
Assignees:
The General Hospital Corporation, The Genetics Institute, Inc.
Inventors:
Roger Brent, John M. McCoy, Timm H. Jessen
Abstract: Purified BMP-6 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
November 9, 1998
Date of Patent:
March 27, 2001
Assignee:
Genetics Institute, Inc.
Inventors:
John M. Wozney, Elizabeth A. Wang, Vicki A. Rosen, Anthony J. Celeste
Abstract: Methods and compositions are provided for the treatment of defects and disease involving the functional attachment of connective tissue, such as tendon or ligament, to bone. Preferred methods comprise administering a composition containing a bone morphogenetic protein and a suitable carrier. The method results in the regeneration of functional attachment between the connective tissue and bone, such that minimal fibrous or granulation tissue is formed at the interface between the regenerated bone and connective tissue. The method and composition are useful for augmenting tissue grafts in reconstructive surgery. The method and compositions result in closer apposition of bone to the connective tissue at earlier time points and increased strength of fixation at earlier time points.
Type:
Grant
Filed:
March 23, 1999
Date of Patent:
February 13, 2001
Assignee:
Genetics Institute, Inc.
Inventors:
John M. Wozney, Scott A. Rodeo, Jo A. Hannafin, Russell F. Warren
Abstract: Purified BMP-3 proteins and processes for producing them are disclosed. They may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
September 5, 1997
Date of Patent:
January 23, 2001
Assignee:
Genetics Institute, Inc.
Inventors:
Elizabeth A. Wang, John M. Wozney, Vicki Rosen
Abstract: Purified Frazzled proteins, including WG67-16, WG67-19 and WA628, and processes for producing them are disclosed. DNA molecules encoding the Frazzled proteins, including WG67-16, WG67-19 and WA628, are also disclosed. The proteins may be used in modulating the binding of Wnt genes to their receptor. They are useful in the modulation of cellular formation, growth, differentiation, proliferation and/or maintenance of a variety of adult and embryonic tissues and organs.
Type:
Grant
Filed:
July 11, 1997
Date of Patent:
December 26, 2000
Assignees:
Genetics Institute, Inc., Whitehead Institute for Biomedical Research
Inventors:
Lisa Racie, Edward Lavallie, Janet Paulsen, Hazel Sive, Benjamin Sun